Analyst Ratings for Protalix BioTherapeutics (PLX) [Neutrals]
PLX Rating Summary
PLX Price Target Summary
- Highest: $9.00 (Auriga)
- Lowest: $5.50 (Jefferies)
- Average: $6.88
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$6.88 (+32.2%)
Avg. $ Target:
$6.88 (+32.2%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/24/2012 | Jefferies » Updated 11/9/2012 |
New Coverage | Hold (N/A) |
5.50 (6.00) |
5.35 | 5.20 | -2.8% | Details |
| 6/25/2012 | Wells Fargo | Downgrade | Market Perform (Outperform) |
N/A (N/A) |
6.19 | 5.20 | -15.99% | Details |
| 6/12/2012 | Aegis Capital | New Coverage | Hold (N/A) |
N/A (N/A) |
6.65 | 5.20 | -21.8% | Details |
| 5/2/2012 | Canaccord Genuity » Updated 8/6/2012 |
Downgrade | Hold (N/A) |
6.00 (6.00) |
7.69 | 5.20 | -32.38% | Details |
| 10/13/2011 | Morgan Joseph | New Coverage | Hold (N/A) |
N/A (N/A) |
4.89 | 5.20 | 6.34% | Details |
| 5/6/2011 | Hapoalim Securities | Upgrade | Hold (N/A) |
N/A (N/A) |
6.54 | 5.20 | -20.49% | Details |
| 2/28/2011 | Capstone Investments | Downgrade | Hold (N/A) |
N/A (N/A) |
7.63 | 5.20 | -31.85% | Details |
| 2/25/2011 | Noble Financial | Downgrade | Hold (N/A) |
N/A (N/A) |
6.70 | 5.20 | -22.39% | Details |
| 2/8/2011 | UBS | Downgrade | Neutral (N/A) |
N/A (N/A) |
10.15 | 5.20 | -48.77% | Details |
